The effects of darifenacin and tolterodine on heart rate (HR) in patients with overactive bladder (OAB)

被引：0
|
作者：
Olshansky, B.
Foote, J.
Arguinzoniz, M.
Lheritier, K.
Quebe-Fehling, E.
Steel, M.
机构：
[1] Univ Iowa Hosp, Iowa City, IA USA
[2] Midtown Urol & Surg Ctr, Atlanta, GA USA
[3] Novartis Pharma AG, Basel, Switzerland
来源：
NEUROUROLOGY AND URODYNAMICS | 2006年 / 25卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
124
引用
收藏
页码：656 / 657
页数：2
相关论文
共 50 条
  • [41] Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerations
    Andersson, Karl-Erik
    Olshansky, Brian
    BJU INTERNATIONAL, 2007, 100 (05) : 1007 - 1014
  • [42] Treating patients with overactive bladder symptoms with antimuscarinics; heart rate considerations
    Wyllie, Michael G.
    BJU INTERNATIONAL, 2008, 101 (01) : 129 - 129
  • [43] Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia - Comment
    Lemack, GE
    UROLOGY, 2006, 67 (04) : 736 - 736
  • [44] A review: Differing costs and effects in economic evaluations of tolterodine for the treatment of overactive bladder
    Snedecor, S. J.
    Botteman, M. F.
    Weinstein, D.
    Trocio, J.
    VALUE IN HEALTH, 2008, 11 (03) : A302 - A302
  • [45] A RANDOMIZED, PLACEBO CONTROLLED, CROSSOVER STUDY TO EVALUATE THE EFFECTS OF TOLTERODINE ON URODYNAMIC PARAMETERS IN PATIENTS WITH OVERACTIVE BLADDER
    Frenkl, Tara
    Railkar, Radha A.
    Shore, Neal
    Bailen, James
    Sutherland, Suzette E.
    Burke, Joanne
    Scott, Boyd B.
    Ruddy, Marcella
    Beals, Chan
    NEUROUROLOGY AND URODYNAMICS, 2010, 29 (02) : 295 - 296
  • [46] Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder
    Drutz H.P.
    Appell R.A.
    Gleason D.
    Klimberg I.
    Radomski S.
    International Urogynecology Journal, 1999, 10 (5) : 283 - 289
  • [47] Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder
    Dmochowski, Roger
    Abrams, Paul
    Marschall-Kehrel, Daniela
    Wang, Joseph T.
    Guan, Zhonghong
    EUROPEAN UROLOGY, 2007, 51 (04) : 1054 - 1064
  • [48] Combined effects of Behavioral intervention and tolterodine in subjects dissatisfied with their overactive bladder medication
    Klutke, C.
    Wyman, J.
    Guan, Z.
    Sun, F.
    Berriman, S.
    Burgio, K.
    INTERNATIONAL UROGYNECOLOGY JOURNAL, 2008, 19 : S54 - S54
  • [49] Retrospective evaluation of outcomes in patients with overactive bladder receiving tolterodine versus oxybutynin
    Jumadilova, Zhanna
    Varadharajan, Sujata
    Girase, Prafulla
    Ollendorf, Daniel A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2006, 63 (23) : 2357 - 2364
  • [50] The Effect of Sacral Neuromodulation (SNM) on Nocturia in patients with Overactive Bladder Syndrome (OAB)
    Attaran, Daemi P.
    Janssen, J. M. W.
    Van Koeveringe, G.
    Vrijens, D.
    Heesakkers, J.
    Saar, M.
    Rahnama'i, M. S.
    EUROPEAN UROLOGY, 2022, 81 : S1258 - S1258
12345